Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Kyeong Jin Kim  (Kim KJ) 7 Articles
Thyroid
Big Data Articles (National Health Insurance Service Database)
Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea
Jung A Kim, Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Endocrinol Metab. 2025;40(1):125-134.   Published online January 13, 2025
DOI: https://doi.org/10.3803/EnM.2024.2093
  • 1,623 View
  • 94 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Antithyroid drug (ATD) treatment is the preferred initial treatment for Graves’ disease (GD) in South Korea, despite higher treatment failure rates than radioactive iodine (RAI) therapy or thyroidectomy. This study aimed to evaluate the incidence of treatment failure associated with the primary modalities for GD treatment in real-world practice.
Methods
We included 452,001 patients diagnosed with GD between 2004 and 2020 from the Korean National Health Insurance Service-National Health Information Database. Treatment failure was defined as switching from ATD, RAI, or thyroidectomy treatments, and for ATD specifically, inability to discontinue medication for over 2 years.
Results
Mean age was 46.2 years, with females constituting 70.8%. Initial treatments for GD included ATDs (98.0%), thyroidectomy (1.3%), and RAI (0.7%), with a noted increment in ATD application from 96.2% in 2004 to 98.8% in 2020. During a median follow- up of 8.5 years, the treatment failure rates were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Multivariate analysis indicated that the hazard ratio for treatment failure with ATD was 2.81 times higher than RAI. RAI treatments ≥10 mCi had 37% lower failure rates than doses <10 mCi.
Conclusion
ATDs are the most commonly used for GD in South Korea, followed by thyroidectomy and RAI. Although the risk of treatment failure for ATD is higher than that of RAI therapy, initial RAI treatment in South Korea is relatively limited compared to that in Western countries. Further studies are required to evaluate the cause of low initial RAI treatment rates in South Korea.

Citations

Citations to this article as recorded by  
  • Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
    Chan-Hee Jung
    Endocrinology and Metabolism.2025; 40(1): 70.     CrossRef
Close layer
Thyroid
Treatment Patterns and Preferences for Graves’ Disease in Korea: Insights from a Nationwide Cohort Study
Kyeong Jin Kim, Jimi Choi, Soo Myoung Shin, Jung A Kim, Kyoung Jin Kim, Sin Gon Kim
Endocrinol Metab. 2024;39(4):659-663.   Published online August 5, 2024
DOI: https://doi.org/10.3803/EnM.2024.2042
  • 2,493 View
  • 126 Download
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Treatment patterns and preferences for patients with Graves’ disease (GD) vary across countries. In this study, we assessed the initial therapies and subsequent treatment modalities employed for GD in real-world clinical practice in Korea. We analyzed 452,001 patients with GD from 2004 to 2020, obtained from the Korean National Health Insurance Service database. Initial treatments included antithyroid drug (ATD) therapy (98% of cases), thyroidectomy (1.3%), and radioactive iodine (RAI) therapy (0.7%). The rates of initial treatment failure were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Even among cases of ATD treatment failure or recurrence, the rates of RAI therapy remained low. Regarding initial treatment, the 5-year remission rate was 46.8% among patients administered ATDs versus 91.0% among recipients of RAI therapy; at 10 years, these rates were 59.2% and 94.0%, respectively. Our findings highlight a marked disparity in the use of RAI therapy in Korea compared to Western countries. Further research is required to understand the reasons for these differences in treatment patterns.

Citations

Citations to this article as recorded by  
  • 2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism
    Kyeong Jin Kim, Eyun Song, Mijin Kim, Hyemi Kwon, Eu Jeong Ku, Hyun Woo Kwon, Jee Hee Yoon, Eun Kyung Lee, Won Woo Lee, Young Joo Park, Dong-Jun Lim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Tae Yong Kim, Sin Gon Kim, Dong Gyu Na, Jee Soo Kim
    International Journal of Thyroidology.2025; 18(1): 65.     CrossRef
Close layer
Thyroid
It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
Kyeong Jin Kim
Endocrinol Metab. 2024;39(1):95-97.   Published online February 22, 2024
DOI: https://doi.org/10.3803/EnM.2024.104
  • 1,968 View
  • 77 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Ultrasonic radiomics in predicting pathologic type for thyroid cancer: a preliminary study using radiomics features for predicting medullary thyroid carcinoma
    Dai Zhang, Fan Yang, Wenjing Hou, Ying Wang, Jiali Mu, Hailing Wang, Xi Wei
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Sleep Duration and the Risk of Type 2 Diabetes: A Community-Based Cohort Study with a 16-Year Follow-up
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Seung Ku Lee, Chol Shin, Nan Hee Kim
Endocrinol Metab. 2023;38(1):146-155.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1582
  • 7,742 View
  • 248 Download
  • 11 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
We aimed to investigate the moderating effects of obesity, age, and sex on the association between sleep duration and the development of diabetes in Asians.
Methods
We analyzed data from a cohort of the Korean Genome and Epidemiology Study conducted from 2001 to 2020. After excluding shift workers and those with diabetes at baseline, 7,407 participants were stratified into three groups according to sleep duration: ≤5 hours/night, >5 to 7 hours/night (reference), and >7 hours/night. The Cox proportional hazards analyses were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes mellitus (T2DM). Subgroup analyses were performed according to obesity, age, and sex.
Results
During 16 years of follow-up, 2,024 cases of T2DM were identified. Individuals who slept ≤5 h/night had a higher risk of incident diabetes than the reference group (HR, 1.17; 95% CI, 1.02 to 1.33). The subgroup analysis observed a valid interaction with sleep duration only for obesity. A higher risk of T2DM was observed in the ≤5 hours/night group in non-obese individuals, men, and those aged <60 years, and in the >7 hours/night group in obese individuals (HRs were 1.34 [95% CI, 1.11 to 1.61], 1.22 [95% CI, 1 to 1.49], and 1.18 [95% CI, 1.01 to 1.39], respectively).
Conclusion
This study confirmed the effect of sleep deprivation on the risk of T2DM throughout the 16-year follow-up period. This impact was confined to non-obese or young individuals and men. We observed a significant interaction between sleep duration and obesity.

Citations

Citations to this article as recorded by  
  • Sleep features and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis
    Hongyi Liu, Hui Zhu, Qinkang Lu, Wen Ye, Tao Huang, Yuqiong Li, Bingqi Li, Yingxin Wu, Penghao Wang, Tao Chen, Jin Xu, Lindan Ji
    Annals of Medicine.2025;[Epub]     CrossRef
  • The potential impact of habitual sleep quality on glycaemic control and inflammation: A study on geriatric patients recently diagnosed with type 2 diabetes mellitus (T2DM)
    Nadia Hussain, Amal Hussain Ibrahim Al Haddad, Saima Abbass, Zina Alfahl
    Sleep Medicine: X.2025; 9: 100139.     CrossRef
  • The link between sleep duration and stroke risk
    Yu Cheng, Yuchuan Ding, Ahmed Elmadhoun, Xunming Ji, Xiaokun Geng
    Brain Circulation.2025; 11(1): 1.     CrossRef
  • Association between obstructive sleep apnea risk and atherosclerosis: A nationwide cross-sectional study in the Korean population
    Il Rae Park, Yong Geun Chung, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Qian Wu
    PLOS One.2025; 20(5): e0322897.     CrossRef
  • Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
    Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(1): 37.     CrossRef
  • Role of Sleep and Sleep Disorders in Cardiometabolic Risk: a Review and Update
    Shaden O. Qasrawi, Ahmed S. BaHammam
    Current Sleep Medicine Reports.2024; 10(1): 34.     CrossRef
  • Evaluating reliability in wearable devices for sleep staging
    Vera Birrer, Mohamed Elgendi, Olivier Lambercy, Carlo Menon
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Replication Study of Genome Wide Association Study of Sleep Duration in Korean Association Resources Cohort
    Seok-Ho Cho, Seon-Ah Kim, Hyun-Seok Jin, Hong Sung Kim
    Biomedical Science Letters.2024; 30(2): 86.     CrossRef
  • Insights into optimal BMI from the GlasVEGAS study
    Chun-Kwan O, Juliana C. N. Chan
    Nature Metabolism.2024; 6(8): 1435.     CrossRef
  • Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer’s disease in elderly
    Upasana Mukherjee, Ujala Sehar, Malcolm Brownell, P. Hemachandra Reddy
    Ageing Research Reviews.2024; 100: 102457.     CrossRef
  • The Relationship Between the Risk of Type 2 Diabetes and Insomnia Severity and Sleep Duration in Academicians
    Tuğba Bilgehan, Esra Çalık Var
    Sağlık Bilimleri Üniversitesi Hemşirelik Dergisi.2024; 6(3): 203.     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The Link Between Sleeping and Type 2 Diabetes: A Systematic Review
    Ali Darraj
    Cureus.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
How Can We Adopt the Glucose Tolerance Test to Facilitate Predicting Pregnancy Outcome in Gestational Diabetes Mellitus?
Kyeong Jin Kim, Nam Hoon Kim, Jimi Choi, Sin Gon Kim, Kyung Ju Lee
Endocrinol Metab. 2021;36(5):988-996.   Published online October 15, 2021
DOI: https://doi.org/10.3803/EnM.2021.1107
  • 6,066 View
  • 123 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We investigated how 100-g oral glucose tolerance test (OGTT) results can be used to predict adverse pregnancy outcomes in gestational diabetes mellitus (GDM) patients.
Methods
We analyzed 1,059 pregnant women who completed the 100-g OGTT between 24 and 28 weeks of gestation. We compared the risk of adverse pregnancy outcomes according to OGTT patterns by latent profile analysis (LPA), numbers to meet the OGTT criteria, and area under the curve (AUC) of the OGTT graph. Adverse pregnancy outcomes were defined as a composite of preterm birth, macrosomia, large for gestational age, low APGAR score at 1 minute, and pregnancy-induced hypertension.
Results
Overall, 257 participants were diagnosed with GDM, with a median age of 34 years. An LPA led to three different clusters of OGTT patterns; however, there were no significant associations between the clusters and adverse pregnancy outcomes after adjusting for confounders. Notwithstanding, the risk of adverse pregnancy outcome increased with an increase in number to meet the OGTT criteria (P for trend=0.011); odds ratios in a full adjustment model were 1.27 (95% confidence interval [CI], 0.72 to 2.23), 2.16 (95% CI, 1.21 to 3.85), and 2.32 (95% CI, 0.66 to 8.15) in those meeting the 2, 3, and 4 criteria, respectively. The AUCs of the OGTT curves also distinguished the patients at risk of adverse pregnancy outcomes; the larger the AUC, the higher the risk (P for trend=0.007).
Conclusion
The total number of abnormal values and calculated AUCs for the 100-g OGTT may facilitate tailored management of patients with GDM by predicting adverse pregnancy outcomes.

Citations

Citations to this article as recorded by  
  • Association between area under the curve of oral glucose tolerance test and the risk of preterm birth among women with gestational diabetes mellitus: a mediation effect of gestational weight gain
    Jing Liu, Huibin Li, Xue Wang, Beibei Liu, Dan He, Gang Zhang, Yan Gao
    BMC Pregnancy and Childbirth.2025;[Epub]     CrossRef
  • Association between the glucose pattern in oral glucose tolerance test and adverse pregnancy outcomes among non-diabetic women
    Fangping Zhou, Binbin Yin, Ya Xi, Jinghua Zhang, Yongying Bai
    Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
  • Risk factors combine in a complex manner in assessment for macrosomia
    Yi-Wen Wang, Yan Chen, Yong-Jun Zhang
    BMC Public Health.2023;[Epub]     CrossRef
  • Association of the Severity of Hypertensive Disorders in Pregnancy with Birthweight, Childhood Obesity, and Blood Pressure at Age 7
    Yan Chen, Yiwen Wang, Yanjun Li, Guodong Ding, Yongjun Zhang
    Nutrients.2023; 15(14): 3104.     CrossRef
Close layer
Miscellaneous
The Status and Distinct Characteristics of Endocrine Diseases in North Korean Articles Published between 2006 and 2015
Kyeong Jin Kim, Shin Ha, Yo Han Lee, Jung Hyun Noh, Sin Gon Kim
Endocrinol Metab. 2018;33(2):268-272.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.268
  • 6,128 View
  • 49 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Past decades of division have led to substantial differences in medical environments between South and North Korea. However, little is known about North Korea's medical status and research field, especially regarding endocrinology. In this study, we report the characteristics of North Korea's articles regarding endocrine-related diseases.

Methods

Among the nine medical journals, articles published in Internal Medicine between 2006 and 2015 were reviewed. A total of 2,092 articles were included; among them, 96 articles were associated with endocrinology. We analyzed these articles according to the disease categories they focused on and evaluated their features.

Results

Articles related to diabetes mellitus accounted for 55.2% (n=53) and those to thyroid disease accounted for 28.1% (n=27). Other disease categories, including adrenal gland (n=1), pituitary gland (n=1), and osteoporosis (n=3), comprised minor portions. Regarding diabetes mellitus, more than half the articles (n=33) focused on treatment and complications. Experimental studies were conducted with old hypoglycemic drugs or natural substances for the treatment of hyperglycemia. Regarding thyroid disease, articles related to hyperthyroidism were the most common (51.9%, n=14), followed by thyroid nodule/cancer (18.5%, n=5). Unique article features were short length, no figures, and less than five references.

Conclusion

North Korea's endocrinology articles mainly focused on diabetes mellitus and thyroid disease. Persistent studies have been carried out in North Korea with dedication despite the poor medical environment. We hope that this study will be the beginning of mutual medical exchange and collaboration between North and South Korea.

Citations

Citations to this article as recorded by  
  • Surgical Diseases in North Korea: An Overview of North Korean Medical Journals
    Sejin Choi, Taehoon Kim, Soyoung Choi, Hee Young Shin
    International Journal of Environmental Research and Public Health.2020; 17(24): 9346.     CrossRef
  • Endocrinology and Metabolism Has Been Indexed in MEDLINE: A Major Achievement
    Won-Young Lee
    Endocrinology and Metabolism.2019; 34(2): 138.     CrossRef
Close layer
Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
Nam Hoon Kim, Dong-Lim Kim, Kyeong Jin Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Endocrinol Metab. 2017;32(2):241-247.   Published online June 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.241
  • 6,268 View
  • 103 Download
  • 26 Web of Science
  • 27 Crossref
AbstractAbstract PDFPubReader   
Background

Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor, vildagliptin, or a thiazolidinedione, pioglitazone, on glycemic variability and oxidative stress in patients with type 2 diabetes.

Methods

In this open label, randomised, active-controlled, pilot trial, individuals who were inadequately controlled with metformin monotherapy were assigned to either vildagliptin (50 mg twice daily, n=17) or pioglitazone (15 mg once daily, n=14) treatment groups for 16 weeks. Glycemic variability was assessed by calculating the mean amplitude of glycemic excursions (MAGE), which was obtained from continuous glucose monitoring. Urinary 8-iso prostaglandin F2α, serum oxidised low density lipoprotein, and high-sensitivity C-reactive protein were used as markers of oxidative stress or inflammation.

Results

Both vildagliptin and pioglitazone significantly reduced glycated hemoglobin and mean plasma glucose levels during the 16-week treatment. Vildagliptin also significantly reduced the MAGE (from 93.8±38.0 to 70.8±19.2 mg/dL, P=0.046), and mean standard deviation of 24 hours glucose (from 38±17.3 to 27.7±6.9, P=0.026); however, pioglitazone did not, although the magnitude of decline was similar in both groups. Markers of oxidative stress or inflammation including urinary 8-iso prostaglandin F2α did not change after treatment in both groups.

Conclusion

In this 16-week treatment trial, vildagliptin, but not pioglitazone, reduced glycemic variability in individuals with type 2 diabetes who was inadequately controlled with metformin monotherapy, although a reduction of oxidative stress markers was not observed.

Citations

Citations to this article as recorded by  
  • Investigating the Genotoxic Potential of Pioglitazone in Hyperglycemic Conditions Using Chromosome Aberration and GADD45α Markers in TK6 Cells
    Darshan T. Valani, Dolatsinh B. Zala, Chetan K. Kajavadara, Laxit K. Bhatt, Hiren M. Patel, Rajesh Sundar, Mukul R. Jain
    Journal of Biochemical and Molecular Toxicology.2025;[Epub]     CrossRef
  • Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review
    Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar
    International Journal of Diabetes and Technology.2024; 3(2): 49.     CrossRef
  • Glycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities
    Yuyan Sun, Bing Lu, Yuanwen Hu, Yingqi Lv, Shao Zhong
    International Journal of General Medicine.2024; Volume 17: 4297.     CrossRef
  • Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus
    Alanood A. Howsawi, Manal M. Alem
    Scientific Reports.2024;[Epub]     CrossRef
  • What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
    Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa
    European Endocrinology.2023; 19(2): 4.     CrossRef
  • Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice
    Antonio Ceriello, Ali A. Rizvi, Manfredi Rizzo
    Advances in Therapy.2022; 39(1): 1.     CrossRef
  • Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study
    Abdulhamza Hmood, Mohammed Almasoody, Hameed Hussein Al-Jameel
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 506.     CrossRef
  • Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
    SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim
    Diabetes and Vascular Disease Research.2022;[Epub]     CrossRef
  • Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
    Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
    Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(5): 689.     CrossRef
  • Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study
    Manal M. Alem
    Heliyon.2022; 8(11): e11549.     CrossRef
  • Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy
    Rajesh Rajput, Suyasha Saini, Siddhant Rajput, Parankush Upadhyay
    Indian Journal of Endocrinology and Metabolism.2022; 26(6): 537.     CrossRef
  • Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
    Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2021; 45(3): 339.     CrossRef
  • Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications
    Bao Sun, Zhiying Luo, Jiecan Zhou
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review
    Anne-Esther Breyton, Stéphanie Lambert-Porcheron, Martine Laville, Sophie Vinoy, Julie-Anne Nazare
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects
    Sahar Hossam Elhini, Amal K. Hussien, Ahmed Abd Elsamie Omran, Asmaa A. Elsayed, Haitham saeed
    Clinical and Experimental Pharmacology and Physiology.2021; 48(12): 1589.     CrossRef
  • Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress
    Fariba Aghahoseini, Alireza Alihemmati, Leila Hosseini, Reza Badalzadeh
    Journal of Diabetes & Metabolic Disorders.2020; 19(2): 701.     CrossRef
  • Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes
    Kristina M. Utzschneider, Tonya N. Johnson, Kara L. Breymeyer, Lisa Bettcher, Daniel Raftery, Katherine M. Newton, Marian L. Neuhouser
    Journal of Diabetes and its Complications.2020; 34(8): 107586.     CrossRef
  • Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
    Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
    Diabetes, Obesity and Metabolism.2020; 22(2): 173.     CrossRef
  • Glycemic variability: adverse clinical outcomes and how to improve it?
    Zheng Zhou, Bao Sun, Shiqiong Huang, Chunsheng Zhu, Meng Bian
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
    Niki Katsiki, Ele Ferrannini
    Journal of Diabetes and its Complications.2020; 34(12): 107723.     CrossRef
  • Impact of long-term glucose variability on coronary atherosclerosis progression in patients with type 2 diabetes: a 2.3 year follow-up study
    Suhua Li, Xixiang Tang, Yanting Luo, Bingyuan Wu, Zhuoshan Huang, Zexiong Li, Long Peng, Yesheng Ling, Jieming Zhu, Junlin Zhong, Jinlai Liu, Yanming Chen
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes
    Xixiang Tang, Junlin Zhong, Hui Zhang, Yanting Luo, Xing Liu, Long Peng, Yanling Zhang, Xiaoxian Qian, Boxiong Jiang, Jinlai Liu, Suhua Li, Yanming Chen
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
    Xin Liu, Peng Men, Bo Wang, Gaojun Cai, Zhigang Zhao
    Lipids in Health and Disease.2019;[Epub]     CrossRef
  • Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
    Fahmida Alam, Md. Asiful Islam, Mafauzy Mohamed, Imran Ahmad, Mohammad Amjad Kamal, Richard Donnelly, Iskandar Idris, Siew Hua Gan
    Scientific Reports.2019;[Epub]     CrossRef
  • Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
    Subin Lee, Heeyoung Lee, Yoonhye Kim, EunYoung Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes
    Guillermo E. Umpierrez, Boris P. Kovatchev
    The American Journal of the Medical Sciences.2018; 356(6): 518.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP